Hospital
Thedacare Medical Center - New London, INC.
Thedacare Medical Center - New London, INC. was paid $9.19M by Medicaid between Jan 2018 and Dec 2024, across 140 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoTHEDACARE MEDICAL CENTER - NEW LONDON, INC.
NEW LONDON, WI 54961
NEW LONDON, WI 54961
33aNPI1538127220assigned 05/02/2006
33bProvider typeCritical Access Hospital
28Total paid$9.19M
24GClaims218,876
24DCodes billed140
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#10 of 48
Median peer was paid$4.30M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FLETT, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,037 | $924K | |
| 2019 | 28,999 | $1.16M | |
| 2020 | 28,043 | $1.12M | |
| 2021 | 37,120 | $1.45M | |
| 2022 | 36,365 | $1.37M | |
| 2023 | 35,029 | $1.59M | |
| 2024incomplete | 27,283 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 14,362 | 12,236 | $2.07M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 7,658 | 6,644 | $1.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 7,053 | 5,612 | $1.19M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 7.3% | 3,263 | 2,316 | $667K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.2% | 1,380 | 1,014 | $573K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 1,971 | 1,713 | $531K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 1,713 | 1,521 | $402K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 3.9% | 1,234 | 866 | $361K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.9% | 2,345 | 2,074 | $358K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.2% | 1,178 | 966 | $205K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 18,385 | 14,075 | $133K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.4% | 1,037 | 761 | $127K |
128 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 4,881 | $119K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,115 | $88K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,977 | $76K |
| 87631 | <1% | 825 | $76K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 220 | $61K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,207 | $54K |
| 80076 | <1% | 8,979 | $50K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 745 | $47K |
| 80061 | Lipid panel | <1% | 3,675 | $41K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 836 | $33K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,173 | $26K |
| G0378 | Hospital observation service, per hour | <1% | 842 | $26K |
| 81025 | <1% | 2,201 | $25K | |
| 84484 | <1% | 4,060 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,776 | $24K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 54 | $23K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 85 | $20K |
| 80306 | <1% | 1,486 | $20K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,205 | $17K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,171 | $17K |
| 96368 | <1% | 56 | $17K | |
| 81001 | <1% | 5,957 | $16K | |
| 83690 | <1% | 3,333 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 192 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,735 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 652 | $14K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 131 | $13K |
| 83735 | <1% | 2,567 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 352 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 369 | $12K |
| 85610 | <1% | 3,839 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,989 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,902 | $12K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 364 | $11K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 160 | $11K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,096 | $10K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 142 | $9K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 30 | $9K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 278 | $8K |
| 80053 | Comprehensive metabolic panel | <1% | 755 | $8K |
| 97162 | <1% | 236 | $7K | |
| 83880 | <1% | 564 | $7K | |
| 85380 | <1% | 1,142 | $7K | |
| 87650 | <1% | 202 | $6K | |
| 85730 | <1% | 1,851 | $6K | |
| 84439 | <1% | 792 | $5K | |
| 87081 | <1% | 72 | $5K | |
| 82077 | <1% | 587 | $5K | |
| 83605 | <1% | 1,135 | $5K | |
| 82948 | <1% | 1,217 | $5K | |
| 87070 | <1% | 549 | $5K | |
| 86140 | <1% | 1,135 | $5K | |
| 81003 | <1% | 1,612 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,615 | $5K |
| 87480 | <1% | 244 | $4K | |
| 87510 | <1% | 245 | $4K | |
| 87660 | <1% | 226 | $4K | |
| 87040 | <1% | 959 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,181 | $3K |
| 82728 | <1% | 345 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,938 | $3K |
| 87186 | <1% | 455 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 191 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 44 | $2K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 16 | $2K |
| 82947 | <1% | 810 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $2K |
| 36592 | <1% | 605 | $2K | |
| 85027 | <1% | 425 | $2K | |
| 80143 | <1% | 145 | $2K | |
| 87807 | <1% | 112 | $1K | |
| 85651 | <1% | 439 | $1K | |
| 80179 | <1% | 126 | $1K | |
| 82570 | <1% | 318 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,208 | $1K |
| 85379 | <1% | 172 | $1K | |
| 84703 | <1% | 187 | $1K | |
| 87088 | <1% | 225 | $1K | |
| 96376 | <1% | 1,137 | $892.38 | |
| 82962 | <1% | 503 | $786.24 | |
| 82150 | <1% | 142 | $722.53 | |
| 85652 | <1% | 332 | $674.97 | |
| 82043 | <1% | 132 | $640.55 | |
| 83540 | <1% | 143 | $601.31 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,460 | $584.43 |
| 83550 | <1% | 105 | $571.58 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 18 | $499.29 |
| 90715 | <1% | 14 | $476.66 | |
| 73130 | <1% | 20 | $432.50 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 157 | $385.81 |
| 73630 | <1% | 50 | $366.04 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,175 | $261.41 |
| 84481 | <1% | 16 | $216.52 | |
| 82607 | <1% | 14 | $202.01 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 12 | $180.75 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,785 | $166.04 |
| 82565 | <1% | 23 | $149.94 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 562 | $138.48 |
| 84460 | <1% | 26 | $129.34 | |
| 85014 | <1% | 57 | $119.84 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,281 | $114.74 |
| J2704 | Injection, propofol, 10 mg | <1% | 299 | $113.44 |
| 73110 | <1% | 13 | $100.16 | |
| 85018 | <1% | 46 | $98.52 | |
| 83615 | <1% | 32 | $97.25 | |
| 82550 | <1% | 19 | $88.47 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 69 | $33.42 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,297 | $32.70 |
| 36416 | <1% | 16 | $31.96 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 807 | $27.86 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,742 | $22.74 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 388 | $14.41 |
| 73610 | <1% | 14 | $12.74 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 203 | $9.51 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 16 | $7.27 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 246 | $6.33 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 18 | $4.81 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 73 | $4.68 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 274 | $4.47 |
| A9270 | Non-covered item or service | <1% | 665 | $2.42 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 887 | $0.01 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 15 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 57 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 84 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 35 | $0.00 |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg | 0% | 19 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 34 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLETT, WILLIAM (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.